Effects of tDCS and tUS on Pain Perception in OA of the Knee

Chronic Pain Clinical Trial

Official title:

Effects of Transcranial Direct Current Stimulation (tDCS) and Transcranial Ultrasound (TUS) on the Perception of Pain and Functional Limitations Due to Osteoarthritis of the Knee.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02330315
• Other study ID #: 2014P002496
• Status: Completed
• Phase: N/A
• Start date: March 2015
• Est. completion date: August 2016

Study information

• Verified date: April 2020
• Source: Spaulding Rehabilitation Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate the effects of transcranial direct current stimulation (tDCS) in conjunction with transcranial ultrasound (TUS) on pain perception and functional limitations in people with osteoarthritis of the knee. The investigators hypothesize that there will be a decrease in pain levels with active stimulation, when compared to sham stimulation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 28
• Est. completion date: August 2016
• Est. primary completion date: June 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Able to provide informed consent to participate in the study.

2. Subjects between 18-85 years old.

3. Diagnosis of chronic osteoarthritis with pain of either the knee as self-reported.

Prior to beginning baseline procedures this must be confirmed by medical records or a letter from the subject's physician. This document may either be brought in by the subject or retrieved by study staff after a medical release form is signed by the subject. After consent, if the subject fails to provide the necessary documentation or it cannot be retrieved by study staff the subject will be considered a screen fail.

4. Existing knee pain in the past 6 months of at least 3 on a 0-10 VAS scale on average.

5. Pain resistant to common analgesics and medications for chronic pain used as initial pain management such as Tylenol, Aspirin, Ibuprofen, Soma, Parafon Forte DCS, Zanaflex, and Codeine.

6. Having the ability to feel pain as self-reported

Exclusion Criteria:

1. Pregnancy or trying to become pregnant in the next 6 months.

2. History of alcohol or drug abuse within the past 6 months as self-reported.

3. Contraindications to transcranial brain stimulation or TUS, i.e. implanted brain medical devices or implanted brain metallic devices.

4. Unstable medical conditions (e.g. uncontrolled diabetes, uncompensated cardiac issues, heart failure or chronic obstructive pulmonary disease).

5. Epilepsy.

6. Use of carbamazepine within the past 6 months as self-reported.

7. Suffering from severe depression (with a score of >30 in the Beck Depression Inventory)

8. History of unexplained fainting spells as self-reported.

9. Head injury resulting in more than a momentary loss of consciousness

10. History of neurosurgery as self-reported.

Related Conditions & MeSH terms

• Chronic Pain
• Osteoarthritis

Intervention

Device:
• transcranial direct current stimulation (tDCS)
Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.
• transcranial ultrasound (TUS)
Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.

Locations

Country	Name	City	State
United States	Spaulding Rehabilitation Hospital	Boston	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
Spaulding Rehabilitation Hospital	Highland Instruments, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in Pain Scale	Changes in the Visual Analogue Scale (VAS) for pain will be measured in order to determine whether anodal transcranial direct current stimulation in conjunction with transcranial ultrasound (applied in a diagnostic mode) is effective in reducing pain in subjects with osteoarthritis knee pain. The investigators will also look at changes in the Von Frey assessment and pain pressure threshold (PPT).	Measured for approximately 2 months
Secondary	Changes in Mood	The investigators will measure safety of tDCS and TUS by measuring changes in the Visual Analog Mood Scale (VAMS).	Measured for approximately 2 months
Secondary	Changes in cognition, attention, and focus	The investigators will monitor the safety of tDCS and TUS in subjects by measuring any changes in cognition, attention, and focus with the California Computerized Assessment Package (CalCap) mini.	Measured for approximately 2 months
Secondary	Adverse Events	At each session, subjects will complete a questionnaire to evaluate potential adverse effects of stimulation (headache, neck pain, mood alterations, and seizures) on a 5-point scale. The scale will also be administered at the follow-ups.	Measured for approximately 2 months
Secondary	Physical Examinations	Trained study staff will perform standard physical examinations at several points throughout the study to ensure subject safety. Baseline findings will be compared to the findings observed at the various time points throughout the study to ensure there are no significant changes that may be study related.	Measured for approximately 2 months
Secondary	Single Leg Standing Balance Test	The investigators will measure how long the subject can stand on one foot in order to measure any changes in balance	Measured for approximately 2 months
Secondary	Knee Proprioceptive Test	Proprioceptive acuity will be assessed by the ability to reproduce passive positioning of the leg with eyes closed.	Measured for approximately 2 months
Secondary	Knee Extensor/Flexor Force Test	The investigators will measure whether there are changes in knee extension/flexion abilities.	Measured for approximately 2 months
Secondary	Knee Range of Motion (ROM)	The knee range of motion (flexion/extension angle) will be recorded with an electrogoniometer and motion analysis capture system.	Measured for approximately 2 months
Secondary	Step Test	Subject will be asked to stand unsupported with the feet parallel to each other and a block 5 cm directly in front of them. Subject will then be advised which leg is the stepping leg and asked to place the whole foot onto the block, then return it fully down to the floor. This procedure will be repeated as fast as possible.	Measured for approximately 2 months
Secondary	Functional Reach Test	The investigators will measure changes in subjects ability to complete the functional reach test across the duration of study.	Measured for approximately 2 months
Secondary	Timed Up and Go Test	The investigators will measure if there are changes in the walking speed of the subject from the beginning of the study to the end.	Measured for approximately 2 months
Secondary	Changes in quality of life	The investigators will use the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) to assess changes in quality of life and physical functioning.	Measured for approximately 2 months
Secondary	Neurological Examinations	Trained study staff will perform standard neurological examinations at several points throughout the study to ensure subject safety. Baseline findings will be compared to the findings observed at the various time points throughout the study to ensure there are no significant changes that may be study related.	Measured for approximately 2 months